The pharmaceutical; medical device and medical supply industry have all been hit hard by Foreign Corrupt Practices Act (FCPA) enforcement actions. Just this summer, enforcement actions were announced against Pfizer which contained several obligations, beyond the 13 point minimum best practices compliance program, that were included in its ‘Enhanced Compliance Obligations’. What are some of the specific issues that make FCPA compliance in these industries so challenging? More importantly what are some of the responses and techniques that compliance professionals can recommend that their companies implement to help protect it from, and mitigate, FCPA compliance risk? If you want to explore these questions, and others, and help get some answers I hope that you can attend next week’s Pharmaceutical Anti-Corruption Compliance Conference in Philadelphia, hosted by Hanson Wade. Rarely has there been an event so targeted to answering the compliance challenges to several related industries.